Erlotinib Resistance With EGFR L858r/Y891d Double Mutation in a Patient With Non–Small Cell Lung Cancer

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.12.031
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Second-Line Erlotinib in an EGFR Mutation-Negative Patient With Non-Small-Cell Lung Cancer

Current Oncology
Oncology
2012English

Predictive Factors in Patients With EGFR Mutation‑negative Non‑small Cell Lung Cancer Treated With Erlotinib

Oncology Letters
Cancer ResearchOncology
2014English

Successful Treatment With Osimertinib and Chemotherapy in a Non–Small Cell Lung Cancer Patient With EGFR Mutation and Meningeal Carcinomatosis

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Spatiotemporal T790M Heterogeneity in a Patient With EGFR-Mutant Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2014English

Non-Invasive Urine Testing of EGFR Activating Mutation and T790M Resistance Mutation in Non-Small Cell Lung Cancer

Experimental Hematology and Oncology
Cancer ResearchOncologyHematology
2015English

Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non–small Cell Lung Cancer Harboring EGFR T790M

Nature Medicine
BiochemistryMedicineGeneticsMolecular Biology
2015English

P2.13-30 High-Dose Icotinib in Advanced Non-Small Cell Lung Cancer With EGFR 21 L858R Mutation: The Randomized, Open-Label INCREASE Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Patient-Reported Outcomes From FLAURA: Osimertinib Versus Erlotinib or Gefitinib in Patients With EGFR-mutated Advanced Non-Small-Cell Lung Cancer

European Journal of Cancer
Cancer ResearchOncology
2020English

Brief Report: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced Non–Small-Cell Lung Cancer With Sensitizing EGFR Mutation

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy